Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14
2020 ◽
Vol 38
(12)
◽
pp. 898
2015 ◽
Vol 3
(Suppl 2)
◽
pp. P447
◽
2013 ◽
Vol 43
(3)
◽
pp. 305-313
◽